H.C. Wainwright Maintains Korro Bio(KRRO.US) With Buy Rating, Cuts Target Price to $15
H.C. Wainwright has reiterated its Buy rating for Korro Bio (KRRO.US) but has adjusted its price target downwards to $15. This indicates a continued positive outlook on the company's stock, despite a reduction in the expected future valuation.
Korro Bio adds AATD treatment candidate to pipeline
Korro Bio Inc. has announced the addition of KRRO-111 to its pipeline for treating alpha-1 antitrypsin deficiency (AATD), a genetic disorder. Preclinical studies have shown that KRRO-111 effectively repairs pathogenic mutations and restores functional AAT protein, reducing aggregated proteins significantly. This advancement follows recent analyst upgrades and a successful financing round, reflecting growing confidence in the company's RNA editing platform.
Citigroup initiates coverage of Korro Bio (KRRO) with buy recommendation
Citigroup has initiated coverage of Korro Bio (KRRO) with a buy recommendation. This signals a positive outlook from the financial institution on the biotechnology company's prospects.
Citi Initiates Korro Bio(KRRO.US) With Buy Rating, Announces Target Price $21
Citi has initiated coverage on Korro Bio (KRRO.US) with a Buy rating. The firm has set a price target of $21 for the company's shares. This indicates a positive outlook from Citi regarding Korro Bio's future performance.
Korro Bio, Inc. advances KRRO-121 RNA editing therapy for hyperammonemia toward clinical stage
Korro Bio, Inc. is making significant progress with KRRO-121, their RNA editing therapy for hyperammonemia, a life-threatening condition caused by excess ammonia in the blood. The company presented the therapy at ASGCT2026, highlighting their commitment to translating RNA editing technology into clinical applications. Korro Bio is actively working to advance KRRO-121 towards clinical trials to address the unmet medical need for patients suffering from hyperammonemia.
Number of shareholders of Korro Bio, Inc. – NASDAQ:KRRO
This article provides details on the number of shareholders for Korro Bio, Inc. (NASDAQ: KRRO). It lists the stock on the Nasdaq Stock Market and refers to its financial overview, news, and other related data on the TradingView platform. The content primarily focuses on the availability of shareholder information without disclosing specific numbers.
JonesTrading Upgrades Korro Bio(KRRO.US) to Buy Rating, Announces Target Price $23
JonesTrading has upgraded Korro Bio (KRRO.US) to a Buy rating from a Hold rating, setting a new price target of $23. This upgrade indicates a strong positive outlook on the company's future stock performance by the firm.
Jones Trading upgrades Korro Bio stock rating on AATD program potential
Jones Trading upgraded Korro Bio Inc. (NASDAQ:KRRO) from Hold to Buy, setting a price target of $23.00, driven by the company's strong first-quarter 2026 results and promising pipeline, particularly its AATD program. The upgrade reflects growing confidence in Korro Bio's future, as evidenced by upward earnings revisions from analysts and advancements in its alpha-1 antitrypsin deficiency and urea cycle disorder candidates. Other firms like Raymond James, Clear Street, and Cantor Fitzgerald have also recently upgraded or reiterated positive ratings for Korro Bio, highlighting its potential in hyperammonemia indications and RNA editing technology.
Chardan Capital Maintains Korro Bio(KRRO.US) With Buy Rating, Maintains Target Price $15
Chardan Capital has reiterated its Buy rating on Korro Bio (KRRO.US) and maintained its target price at $15. This indicates continued confidence from the firm in Korro Bio's stock performance and future prospects.
Korro Bio, Inc. 1Q 2026: Revenue $0M, EPS $(1.69) — 10-Q Summary
Korro Bio, Inc. reported its first-quarter 2026 results, showing $0M in revenue and a net loss of $19.6M. The company improved its diluted loss per share to $(1.69) compared to the previous year, attributing it to paused collaboration revenue from Novo Nordisk and reduced R&D spending. Korro Bio also highlighted pipeline progress for KRRO-121, advancements in its OPERA RNA editing platform, and extended its cash runway into H2 2028 through recent capital raises.
Korro Bio (KRRO) trims R&D spend and boosts cash to $157M
Korro Bio reported a reduced net loss of $19.6 million in Q1 2026 compared to $23.4 million a year earlier, primarily due to decreased research and development and general and administrative costs. The company's cash reserves rose to $157.1 million after a private placement and at-the-market share sales, extending its operational runway into the second half of 2028. This financial boost supports advancing its OPERA RNA-editing platform and lead program KRRO-121 towards human trials, despite a 12-month pause in collaboration revenue from Novo Nordisk.
Korro Reports First Quarter 2026 Financial Results and Provides Corporate Update
Korro Bio, Inc. reported its first-quarter 2026 financial results, highlighting significant scientific progress in its RNA editing platform. The company is advancing its lead program, KRRO-121, for hyperammonemia, with a regulatory filing expected in the second half of 2026, and a GalNAc-conjugated oligonucleotide for alpha-1 antitrypsin deficiency. Korro also completed an oversubscribed $85 million private placement, extending its cash runway into the second half of 2028.
Korro raises $85M, targets 2026 filing for rare-disease drug
Korro Bio, Inc. reported its Q1 2026 financial results, including a net loss of $19.6 million, but strengthened its cash position to $157.1 million after an oversubscribed $85 million private placement. The company is on track for a regulatory filing for its lead program, KRRO-121, in the second half of 2026, targeting hyperammonemia, and anticipates its cash runway will extend into the second half of 2028. Additionally, Korro announced significant progress in its GalNAc AATD program with over 90% in vivo RNA editing, with a development candidate expected in Q2 2026.
Korro Bio (Nasdaq: KRRO) boosts cash to $157M and targets 2026 KRRO-121 filing
Korro Bio reported strong first-quarter 2026 results, boosting its cash reserves to $157.1 million after an $85 million private placement, which is expected to fund operations into the second half of 2028. The company is advancing its lead candidate, KRRO-121, towards a regulatory filing in the second half of 2026 for hyperammonemia, and showcased significant progress in its AATD program with over 90% in vivo RNA editing. Korro Bio's R&D expenses and net loss both decreased year-over-year, reflecting financial improvements and pipeline advancements.
Korro CEO and top executives line up two investor fireside chats
Korro Bio, Inc. (Nasdaq: KRRO) announced that its CEO, Ram Aiyar, and other top executives will participate in two investor conferences in May 2026. These include the HCW BioConnect Nasdaq Investor Conference on May 19th and the RBC Capital Markets Global Healthcare Conference on May 20th, where they will engage in fireside chats to discuss the company's OPERA platform and strategic developments. Korro is a biopharmaceutical company focused on developing genetic medicines for rare and prevalent diseases using its novel RNA editing platform.
Korro Bio Inc expected to post a loss of $1.84 a share - Earnings Preview
Korro Bio Inc (KRRO) is anticipated to report an earnings loss of $1.84 per share. This information comes from a Refinitiv earnings preview. The article is a brief news update regarding the company's financial expectations.
Korro announces oversubscribed $85 million private placement
Korro Bio, Inc. (NASDAQ: KRRO) has announced an oversubscribed private placement, raising $85 million. The funding will support the development of its RNA editing platform and pipeline, including a lead program for Alpha-1 Antitrypsin Deficiency. This strategic move aims to strengthen the company's financial position and accelerate its therapeutic programs.
[ARS] Korro Bio, Inc. SEC Filing
This article announces an ARS SEC filing for Korro Bio, Inc. (KRRO), detailing it as a low impact with neutral sentiment, submitted on April 16, 2026, at 7:10 AM. It provides company details like market cap, industry, and recent news and filings.
Korro brings ammonia and liver disease data to 4 spring conferences
Korro Bio (Nasdaq: KRRO) announced it will present data from its OPERA® oligonucleotide RNA editing platform at four upcoming scientific conferences in April and May 2026. The presentations will cover preclinical models for hyperammonemia, Alpha-1 Antitrypsin Deficiency (AATD) RNA editing, ALS TDP-43 biology, platform chemistry innovations, and healthcare utilization in hepatic encephalopathy. The news led to a mild negative market reaction, with KRRO declining 1.54% on the day of publication.
Korro Bio (KRRO) outlines 2026 virtual meeting, director elections and pay vote
Korro Bio (KRRO) announced its upcoming 2026 virtual annual shareholder meeting on June 10, 2026, where stockholders will vote on the election of two Class I directors, a non-binding advisory resolution on executive compensation, and the ratification of Ernst & Young LLP as the independent auditor. The proxy statement details board structure, corporate governance, and 2025 executive compensation figures for named officers including CEO Ram Aiyar. The company also disclosed recent PIPE financings and related party transactions.
Korro Announces Oral and Poster Presentations at Upcoming Scientific Conferences
Korro Bio, Inc. announced upcoming oral and poster presentations at several scientific conferences, including the American Society of Gene and Cell Therapy 29th Annual Meeting, TIDES USA 2026, the 3rd International Conference on Ureagenesis Defects and Allied Conditions, and the EASL Congress 2026. These presentations will highlight data from Korro's oligonucleotide delivery-based RNA editing technology (OPERA®) and its potential in treating diseases like hyperammonemia and Alpha-1 Antitrypsin Deficiency, as well as addressing TDP-43 aggregation in ALS models.
Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule - Cambridge Today
Korro Bio, a biopharmaceutical company, announced an inducement grant of non-statutory stock options for 15,000 shares to a new employee. This grant, with a 10-year term and a 4-year vesting schedule, is a common practice in the biotech industry to attract and retain talent. It aligns employee interests with shareholder interests, emphasizing Korro Bio's commitment to securing top professionals for its RNA editing platform.
Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Korro Bio, Inc. has announced the grant of a non-statutory stock option to a new employee. This inducement grant, approved by independent directors, allows the employee to purchase 15,000 shares of Korro's common stock at $13.46 per share, vesting over four years. The grant complies with Nasdaq Listing Rule 5635(c)(4), supporting the company's focus on developing genetic medicines through RNA editing.
New Korro Bio hire gets stock option for 15,000 shares under Nasdaq rule
Korro Bio (Nasdaq: KRRO) announced it granted a nonstatutory stock option for 15,000 shares to a newly hired employee at an exercise price of $13.46 per share, the closing price on April 8, 2026. This inducement grant, approved by independent directors under Korro's 2026 Inducement Plan, vests over four years and aligns with Nasdaq Listing Rule 5635(c)(4). The company noted this is a routine corporate update with limited fundamental impact compared to prior financing events.
Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Korro Bio, Inc. announced the issuance of a non-statutory stock option to a new employee. This grant, involving 15,000 shares at an exercise price of $13.46, was made as an inducement for employment in accordance with Nasdaq Listing Rule 5635(c)(4) and vests over four years. Korro Bio is a biopharmaceutical company focused on developing genetic medicines using RNA editing for various diseases.
KRRO|Korro Bio Inc|Price:13.460|Chg%:-0.45
This article provides key financial information for Korro Bio Inc (KRRO), including its current stock price, market cap, and recent performance. It also lists upcoming earnings details for FY2025, analyst ratings (BUY), and outlines sections for income statements, balance sheets, and cash flow statements, noting that relevant data has not yet been disclosed by the company.
KRRO Financials: Revenue Breakdown, Margins & Competitor Comparison
This article provides an overview of Korro Bio Inc's (KRRO) financial performance, focusing on its profitability margins and comparing them to competitors DERM and MENS. KRRO exhibits a high gross margin but significant negative operating and net margins, alongside a negative Return on Equity, indicating challenges in converting operations into shareholder value. The company, with a market capitalization of $201.92M, shows a strong gross margin compared to DERM.
Lynx1 fund tied to Weston Nichols adds Korro Bio (KRRO) position
Lynx1 Master Fund LP, associated with Lynx1 Capital Management LP and Weston Nichols, has purchased 520 shares of Korro Bio, Inc. (KRRO) common stock at $10.60 per share, as reported in a recent SEC Form 4 filing. This transaction brings their indirect holdings to 1,538,296 shares. Both Lynx1 Capital Management LP and Weston Nichols disclaim beneficial ownership except for any pecuniary interest.
Lynx1 and Weston Nichols report 1.54M shares in Korro Bio (NASDAQ: KRRO)
Lynx1 Capital Management LP and Weston Nichols have filed an amended passive investment disclosure (Schedule 13G/A) for Korro Bio, Inc. (NASDAQ: KRRO). They reported beneficial ownership of 1,538,296 shares of Common Stock, which represents a 10.7% stake in the company. This ownership includes shared voting and shared dispositive power over the shares, based on 14,422,571 shares outstanding as of March 11, 2026.
Lynx1 Capital buys Korro Bio (KRRO) shares worth $5512
Lynx1 Capital Management L.P., a ten percent owner of Korro Bio, Inc. (NASDAQ:KRRO), recently purchased 520 shares for $5,512, at a price of $10.60 per share. This transaction led to a 30% gain as the stock climbed to $13.85, contributing to KRRO's significant weekly and year-to-date returns. The company has also secured $85 million in private equity financing and received multiple analyst upgrades, reflecting optimism from both investors and analysts.
KRRO Price Today: Korro Bio, Inc. Stock Price, Quote & Chart
Korro Bio, Inc. (KRRO) is currently trading at $11.32, remaining unchanged from its previous close. The stock has seen a +5.26% return over the past month but experienced a -29.06% price change over the last 12 months, indicating weak performance. Korro Bio, Inc. is a biopharmaceutical company focused on developing genetic medicines through RNA editing for various diseases.
JPMorgan Chase & Co. Buys 196,079 Shares of Korro Bio, Inc. $KRRO
JPMorgan Chase & Co. significantly increased its stake in Korro Bio, Inc. by 6,185.5% in the third quarter, acquiring an additional 196,079 shares to a total of 199,249 shares valued at $9.54 million. This move coincides with substantial insider buying, as two major shareholders each bought 207,100 shares in March, contributing to a total of 1.66 million insider purchases worth $18.4 million over the last 90 days. Despite this investor confidence, Korro Bio reported an unprofitable Q4 with an EPS of ($5.32).
Korro Bio, Inc. (NASDAQ:KRRO) Given Average Recommendation of "Moderate Buy" by Brokerages
Eleven research firms have given Korro Bio, Inc. (NASDAQ:KRRO) a consensus "Moderate Buy" rating, with an average 12-month target price of $37.29. This comes despite the company missing its Q4 EPS estimates significantly, reporting ($5.32) versus ($1.93) estimated, and having negative net margins. Insiders, notably Edward T. Mathers and Paul Edward Walker, recently purchased substantial shares, increasing their ownership to 4.60%.
Vanguard (KRRO) reports zero beneficial ownership after realignment
The Vanguard Group has filed an amendment to a Schedule 13G/A, reporting 0% beneficial ownership of Korro Bio (KRRO) common stock. This change is due to an internal realignment on January 12, 2026, where certain Vanguard subsidiaries will now report their holdings separately, as permitted by SEC Release No. 34-39538. Vanguard itself no longer claims beneficial ownership over securities held by these realigned subsidiaries.
Korro Bio stock gains after tough 2025 - new drug candidate, analyst upgrades boost outlook
Korro Bio's stock experienced gains following a challenging 2025, driven by the announcement of a new drug candidate and positive analyst upgrades. These developments suggest an improved outlook for the company after a difficult previous year.
[EFFECT] Korro Bio, Inc. SEC Filing
This article reports on an SEC filing (Form EFFECT) by Korro Bio, Inc. (KRRO) which was declared effective on March 20, 2026, at 4:15 P.M. The filing indicates a Neutral impact and sentiment for the company. It also provides an overview of Korro Bio's stock data, recent news, and other SEC filings.
Korro Bio, Inc. (KRRO) Reports Q4 Loss, Lags Revenue Estimates
Korro Bio, Inc. (KRRO) reported a significant Q4 loss of $5.32 per share, far exceeding the Zacks Consensus Estimate of a $1.93 loss, and missed revenue estimates with $1.29 million against an expected $1.5 million. The company's stock has seen a 46.8% increase year-to-date, but its earnings outlook remains unfavorable, leading to a Zacks Rank #4 (Sell). Investors are advised to consider the industry outlook and upcoming estimate revisions.
Korro Bio (NASDAQ: KRRO) registers 7.65M shares for resale after $85M private placement
Korro Bio (NASDAQ: KRRO) has registered 7,650,764 shares of common stock for resale following an $85 million private placement that closed on March 10, 2026. This registration includes 4,501,928 common shares and 3,148,836 shares issuable upon the exercise of pre-funded warrants. The company will not receive proceeds from the sale of these shares by the selling stockholders, except for a nominal exercise price from pre-funded warrants.
Korro Bio, Inc. (KRRO) reports Q4 loss, lags revenue estimates
Korro Bio, Inc. (KRRO) announced its Q4 earnings, reporting a loss that was narrower than anticipated by Wall Street analysts but failing to meet revenue expectations. The biotechnology company reported an adjusted loss per share of -$0.98 against an estimated -$1.00, while its revenue of $1 million fell short of the projected $6.83 million.
Analysts Offer Insights on Healthcare Companies: Korro Bio (KRRO), Oruka Therapeutics (ORKA) and Gilead Sciences (GILD)
Analysts have provided insights on several healthcare companies, including Korro Bio (KRRO), Oruka Therapeutics (ORKA), and Gilead Sciences (GILD). Korro Bio and Oruka Therapeutics received "Strong Buy" consensus ratings with significant upside potential, while Gilead Sciences received a "Strong Buy" consensus but a "Hold" rating from one analyst. Price targets and analyst performance metrics were also detailed for each company.
Korro Bio Stock Gains After Tough 2025 - New Drug Candidate, Analyst Upgrades Boost Outlook
Korro Bio's shares gained after a challenging 2025, driven by financial results, a new lead drug candidate KRRO-121 for hyperammonemia, and analyst upgrades. Despite a net loss in 2025, the company has a cash position expected to last until late 2028 and increased collaboration revenue with Novo Nordisk. Analysts from Raymond James and Cantor Fitzgerald upgraded their ratings and price forecasts, signaling a more positive outlook for the company's future.
Analysts Offer Insights on Healthcare Companies: Korro Bio (KRRO), Sagimet Biosciences, Inc. Class A (SGMT) and Bristol-Myers Squibb (BMY)
This article provides analyst insights on three healthcare companies: Korro Bio (KRRO), Sagimet Biosciences, Inc. Class A (SGMT), and Bristol-Myers Squibb (BMY). Ryan Deschner of Raymond James upgraded Korro Bio to Buy, while Jay Olson of Oppenheimer maintained a Buy rating on Sagimet Biosciences. Bernstein's Courtney Breen maintained a Hold rating on Bristol-Myers Squibb.
Korro Bio (KRRO) Losses Of US$117.3 Million Test Bullish Narratives On Profitability
Korro Bio (KRRO) reported a net loss of US$117.3 million and a basic EPS loss of US$12.48 for FY 2025, with Q4 revenue of US$1.3 million. The company's revenue base remains small at US$6.4 million, and losses have widened despite revenue growth in earlier quarters. Bearish arguments suggest continued pressure on the bottom line, with forecasts indicating revenue decline and a high P/S multiple compared to peers, raising concerns about future dilution risks.
Korro Bio (KRRO) sellers register 7.65M common shares after $85M private placement
Korro Bio (KRRO) has filed a shelf registration to allow selling stockholders to resell up to 7.65 million common shares, which includes common shares and pre-funded warrants issued during a March 9, 2026 private placement that raised $85 million. The company clarified that it will not receive proceeds from these secondary resales, except for a nominal exercise price from cash exercises of pre-funded warrants. The registration outlines the distribution plan for these shares, specifying that selling stockholders can use various methods from open market transactions to privately negotiated sales.
Korro Bio (KRRO) major holder adds stock and pre-funded warrants in March 2026 buy
Edward T. Mathers, an affiliated manager of major holder New Enterprise Associates 17, L.P., acquired additional Korro Bio (KRRO) securities on March 10, 2026. This transaction included 242,945 Pre-Funded Warrants and 207,100 shares of Common Stock, documented in an SEC Form 4 filing. Following these purchases, indirect holdings of Common Stock totaled 1,297,893 shares.
Major Korro Bio (KRRO) holder adds shares and pre-funded warrants in March 10 Form 4
New Enterprise Associates 17, L.P. (NEA 17), a significant indirect holder of Korro Bio (KRRO), acquired 242,945 Pre-Funded Warrants and 207,100 shares of Common Stock on March 10, 2026. These transactions, detailed in a Form 4 filing, involved prices of approximately $11.11 per warrant and share, respectively. Following these purchases, NEA 17 indirectly holds 1,297,893 shares of Common Stock, with the warrants being exercisable subject to a 9.99% ownership cap.
Korro Bio (KRRO) Losses Of US$117.3 Million Test Bullish Narratives On Profitability
Korro Bio (KRRO) reported a net loss of US$117.3 million and a basic EPS loss of US$12.48 for the trailing 12 months, with quarterly net losses in FY 2025 ranging from US$18.1 million to US$50.0 million. The company's small revenue base of US$6.4 million, coupled with forecasts of a 45.8% annual decline in revenue for the next three years, challenges bullish narratives. Furthermore, Korro Bio's high Price-to-Sales (P/S) ratio of 28.9x, significantly higher than peers, and substantial shareholder dilution, raise concerns for investors given its unprofitability.
Cantor Fitzgerald raises Korro Bio stock price target on UCD confidence
Cantor Fitzgerald reaffirmed an Overweight rating on Korro Bio Inc. (NASDAQ:KRRO) and increased its price target to $22.00, citing enhanced confidence in the company’s urea cycle disorder (UCD) clinical development program. Korro Bio plans to file an IND/CTA for KRRO-121 in hyperammonemia in patients with UCD and hepatic encephalopathy in the second half of 2026, with Phase 1 study design details to follow the filing. This positive outlook is further supported by recent successful private equity financing and upgrades from other analysts like Raymond James, Clear Street, and H.C. Wainwright, reflecting growing confidence in Korro Bio's RNA editing therapeutics.
Raymond James upgrades Korro Bio stock rating on hyperammonemia pivot
Raymond James upgraded Korro Bio Inc. (NASDAQ:KRRO) from Market Perform to Outperform, setting a price target of $23.00, due to the company's strategic pivot into hyperammonemia indications. This upgrade follows positive preclinical data and an $85 million PIPE financing, extending Korro Bio's cash runway and offering a clear path to potential proof-of-concept for its promising new programs. The company also received similar upgrades from Clear Street, H.C. Wainwright, and Piper Sandler, reflecting growing confidence in its innovative approach to treating complex liver conditions.
Korro Bio (KRRO) secures $85M PIPE to extend cash runway into 2028
Korro Bio has secured an $85 million private investment in public equity (PIPE) financing, significantly extending its cash runway into the second half of 2028. This capital infusion, combined with existing cash, will fund the advancement of its RNA editing pipeline, including clinical data for KRRO-121 in urea cycle disorders, a GalNAc-conjugated alpha-1 antitrypsin deficiency program, and a longevity and liver health program. The financing involved selling common stock and pre-funded warrants to institutional investors, led by Venrock Healthcare Capital Partners.
